Kai Zhao, PhD, director of the Nasal Physiology and Therapeutic Center in the Department of Otolaryngology at Ohio State University College of Medicine, discusses how patients who have experienced a loss of taste and smell following COVID-19 infection may be impacted by this symptom for years without realizing it.
Two medical professionals reveal what factors into intensive chemotherapy consideration and common toxicities found when undergoing treatment.
Cole McCoy, PharmD, shares recent changes in the AML treatment landscape, including updates to the NCCN guidelines.
Drs Preetesh Jain and Michael Wang exchange insights regarding the current and prospective treatment options for patients with Mantle Cell Lymphoma.
Dr Haumschild, PharmD, MS, MBA leads a panel of experts identifying characteristics unique to MCL and addressing initial treatment strategies.
Anna Pham, PharmD, PGY2 ambulatory care resident at Intermountain Healthcare, discusses the role of ambulatory care pharmacists in primary care clinics.
The ATHENA-MONO trial is investigating the use of rucaparib as front line maintenance treatment in ovarian cancer.
Aimee Banks, PharmD, BCPS, MSCS, clinical pharmacist in the Multiple Sclerosis Clinic at Vanderbilt University Medical Center, discusses the role of the pharmacists in patient care, improving outcomes, and managing transitions of care.
Expanded glomerular filtration rate (GFR) testing in the United States could be one step toward minimizing disparities in renal formulas, Beumer said.
The step-up dosing approach with glofitamab in a phase 1 trial enabled researchers to minimize cytokine release syndrome while maximizing outcomes.
Jeff Betcher, BSPharm, MBA, director of pharmacy at Mayo Clinic in Arizona, discusses how automated chemotherapy dose rounding can help decrease drug waste and cost.
Tina Saleh, PharmD, PGY1 specialty pharmacy resident at the University of Illinois Hospital and Health Science System, discusses how oral anticancer agents differ from infusions and how pharmacists can improve tolerability for patients.
Cole McCoy, PharmD, and James McCloskey, MD, explain common treatment goals, cytogenetic tests, and considerations that factor into choosing individualized treatment for patients with AML.
James McCloskey, MD, and Danielle Marcotulli, APN, RN, MSN, FNP-BC, AOCNP give a brief synopsis of AML, including its definition, the different types of the condition, and a typical patient’s journey.
Angela Livingood, PharmD, MHA, BCGP, CPHQ, diversion specialist at Novant Health, discusses what drug diversion is and why it is important for pharmacists to be aware of it.
Brooke Looney, PharmD, certified specialty pharmacist in the Oncology Clinic at Vanderbilt Specialty Pharmacy, discusses medication changes and adverse events for patients starting encorafenib and binimetinib.
Nicholas Robert, MD, chief medical officer at Ontada, discussed disparities in biomarker testing and how they are being addressed.
Kayla Cierniak, PharmD, MS, BCPS, FISMP, medication safety officer in oncology at Seidman Cancer Center discusses the Bar Code Medication Administration and some challenges the initiative faced.
Arpit Mehta, PharmD, MPh, MHA, director of Pharmacy at Allegheny General Hospital, discusses innovations in health-system patient care models to improve patient outcomes.
Katherine Harte, PharmD, a PGY2 ambulatory care pharmacy resident at the Rhode Island Hospital in Providence, Rhode Island, discusses the impact of pharmacist management on SGLT2 inhibitors and GLP-1 receptor agonist utilization in patients with type 2 diabetes mellitus.
Although it has clear benefits when monitoring and managing cancer, Feinberg said more widespread use of circulating tumor DNA will take time.
Aimee Banks, PharmD, BCPS, MSCS, clinical pharmacist in the Multiple Sclerosis Clinic at Vanderbilt University Medical Center, discusses new hematology, oncology, and autoimmune therapies in the pipeline that pharmacists should be aware of.
Five-year progression-free survival in the CLL14 trial is approximately 63% in the targeted treatment arm, according to new data.
Medication adherence is critical to control the symptoms of congestive heart failure.
Blinded independent central review analysis also adds confidence to the findings.
The ability to measure GFR would be a significant advancement for clinicians in the United States.
Beth Koselke, PharmD, BCOP, discusses the impact of pharmacist intervention in clinical trial enrollment, specifically in the MYLUNG Consortium.
Nicholas Robert, MD, chief medical officer at Ontada, discusses disparities in biomarker testing and how they are being addresses at ASCO 2022 Annual Meeting.
New results from the ATHENA-MONO trial investigating the use of rucaparib in patients with ovarian cancer show promise.
The trial achieved a complete remission rate of 39.4%, which researcher Michael Dickinson, MBBS, DMedSci, called "remarkable."
